Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
about
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsThe role of PARP in DNA repair and its therapeutic exploitationEpigenetic changes during cell transformationBRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsSingle cell resolution in vivo imaging of DNA damage following PARP inhibitionA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursPattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinomaFunctional characterisation of a novel ovarian cancer cell line, NUOC-1.Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk.Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancerCediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.Antineoplastic effect of decoy oligonucleotide derived from MGMT enhancer.The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib.Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.Drug therapy for hereditary cancersResponse of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury.The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.Exploiting base excision repair to improve therapeutic approaches for pancreatic cancerBRCA mutation testing in determining breast cancer therapy.BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE studyQuantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.Combination drug delivery approaches in metastatic breast cancerBRCA1 Mutation: A Predictive Marker for Radiation Therapy?Uterine carcinosarcoma/malignant mixed Müllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy.Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancersBRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomasCommon cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
P2860
Q26851765-9C8889BF-6076-4D9F-BA31-D936E1AF5EB2Q26852274-61361BB4-34F3-4D3D-81F7-862BC4664E12Q27002399-901A4AE1-D054-42DD-8913-F2EA5F05904FQ27002968-EF2D4640-F9C3-46EB-B196-A2FCA323BF16Q27851697-C56B74E9-2028-4FA8-8473-94B9D4D83ADFQ28066320-529362BD-9822-4F60-BE22-7901FAD9960AQ28072204-989AF3FF-0A32-492C-BE1D-E72C84A22CD2Q28075761-F08C7E23-F394-4BFE-8DDE-54329A4CDED1Q28598343-1A1AB1A8-4B9F-4A84-BDEA-0AE83CFBF259Q30650918-869B6A49-E6F2-4EC0-AB4B-A0CFC163E51EQ33439527-3A809423-924A-4CEA-93B0-3371C602A704Q33631833-1A02A3D2-DFF5-4C09-9EB7-C20C7C2E1759Q33688843-3AFD4D38-4A0B-46B9-BFF9-24434958EE91Q33810401-C5DBE16D-77F9-48DB-B237-DCB92081F9BAQ33851843-B3E357A0-3FEE-42F1-9393-5D4E6D4D2A32Q33877435-41647A7D-7674-48E3-AB51-097322E52857Q34104143-B993B42E-E851-4EAC-9182-E324B2B3DC6BQ34493362-97DA9F5B-6BC1-4214-AC5D-3815E9DEA529Q34514973-8AF0246A-5357-4DCC-A725-A7F89365A41DQ34612054-F50F6B81-46D5-4DD6-B1B0-3B0A48FF8240Q34735951-EA5DC00D-9537-4331-B8DD-88911C5F8093Q34993640-F96E6C72-BE2A-408D-A7DB-F26C6D5F68E6Q35051154-B688E0BF-A963-49E3-8267-ACC9E935021FQ35051517-4DF66EA8-E6D6-43C6-AC90-9D3CF6F10F63Q35140600-09E85CC7-58F1-40D5-83AD-8B83F42FCBCAQ35208929-756003C8-EEB8-4278-A2E4-FF1ED511F745Q35353424-49FD3229-67FD-4084-A06C-F5AC4229B61BQ35514172-F1EE2AD8-D447-4E03-89C9-93D95A850C03Q35534509-95667E39-1E33-4834-923F-E404382205E6Q35596477-87191781-603B-422F-A1AD-39455E15D24AQ35619225-BAF377B9-ECCE-4A37-9FFF-BC22D8AE5600Q35630278-BB52499D-FD80-432E-8776-F32BB9F7EDFDQ35683623-FAD9B602-68E2-4D73-870F-6B3EAEF5CBF1Q35955198-F376AFFB-CB70-4DA6-929E-F0C5B190ABDDQ36076772-E3D82B48-8889-49C9-B7DA-4B7B4EB75130Q36205570-0B78ABB5-BCF9-41AC-A9D5-65686BD9BEEEQ36356952-3D81E9F0-F8BA-4A0E-BC9B-A50A44624725Q36402747-CB629E51-2B49-45C4-846D-3CA12345A6DBQ36493279-48A4136A-0244-4541-9B8A-BDB6BD72D822Q36544857-DFA283CD-23A7-48C5-A650-C9657A2F6187
P2860
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Therapeutic potential of poly
@nl
Therapeutic potential of poly( ...... or methylated BRCA1 or BRCA2.
@en
type
label
Therapeutic potential of poly
@nl
Therapeutic potential of poly( ...... or methylated BRCA1 or BRCA2.
@en
prefLabel
Therapeutic potential of poly
@nl
Therapeutic potential of poly( ...... or methylated BRCA1 or BRCA2.
@en
P2093
P2860
P356
P1476
Therapeutic potential of poly( ...... d or methylated BRCA1 or BRCA2
@en
P2093
Asima Mukhopadhyay
Elizabeth R Plummer
Evan A Mulligan
Gerrit Los
Huw D Thomas
Richard J Edmondson
Samra Kahn
Suzanne Kyle
Wan-Tse Vong
Yvette Drew
P2860
P304
P356
10.1093/JNCI/DJQ509
P407
P577
2010-12-23T00:00:00Z